Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 6/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | ROS1 | P08922 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5166513 | 0.87 | ELANE (0.41) | — | |
| SCHEMBL5165708 | 0.86 | FPR2 (0.40) | FPR2 | |
| SCHEMBL5163829 | 0.85 | FPR2 (0.41) | FPR2 | |
| SCHEMBL5167396 | 0.82 | FPR2 (0.43) | TRPV4FPR2 | |
| SCHEMBL22411045 | 0.82 | ELANE (0.36) | FPR2 | |
| SCHEMBL5167675 | 0.82 | ELANE (0.35) | FPR2 | |
| SCHEMBL5163750 | 0.81 | ELANE (0.36) | FPR2 | |
| SCHEMBL5166258 | 0.81 | ELANE (0.36) | FPR2 | |
| SCHEMBL5166374 | 0.81 | ELANE (0.38) | FPR2 | |
| SCHEMBL5166623 | 0.81 | ROCK2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025421-A1 | Pyridyl piperazines for the treatment of CNS disorders | PFIZER INC | 2006-02-02 | — | — | US | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| EP-1768975-A2 | PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060025421-A1 | Pyridyl piperazines for the treatment of CNS disorders | PFIZER INC | 2006-02-02 | — | — | US | disclosed |
| WO-2006000912-A2 | PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025421-A1 | Pyridyl piperazines for the treatment of CNS disorders | TPH2, HTR1A, TPH1 | LIPE 4368/4885TRPV4 642/4885SCN2A 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.